Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group

Kevin Marsh (1) , Janine van Til (2) , Elizabeth Molsen-David (3) , Christin Juhnke (4) , Natalia A. Hawken (5) , Elisabeth Oehrlein (6) , Christy Choi (7) , Alejandra Duenas (8, 9) , Wolfgang Greiner (10) , Kara Haas (11) , Mickael Hiligsmann (12) , Kimberley Hockley (13) , Ilya Ivlev (14) , Frank Liu (15) , Jan Ostermann (16) , Thomas Poder (17) , Jiat Poon (18) , Axel Muehlbacher (4)

1 Evidera
2 University of Twente
3 ISPOR
4 HSNB - Hochschule Neubrandenburg
5 Modus Outcomes
6 National Health Council
7 Department of Pharmaceutics, College of Pharmacy, University of Minnesota
8 ICN Business School
9 CEREFIGE - Centre Européen de Recherche en Economie Financière et Gestion des Entreprises
10 Universität Bielefeld = Bielefeld University
11 Cerenovus
12 Maastricht University [Maastricht]
13 Imperial College London
14 Kaiser Permanente
15 Merck & Co. Inc - Merck Sharp and Dohme
16 University of South Carolina [Columbia]
17 CHUS - Centre de recherche Humanités et Sociétés
18 Eli Lilly and Company [Indianapolis]

This study examines European decision makers' consideration and use of quantitative preference data.

Domaines: Gestion et management; Sciences de l'Homme et Société

Kevin Marsh, Janine van Til, Elizabeth Molsen-David, Christin Juhnke, Natalia A. Hawken, et al.. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group. Value in Health, 2020, 23 (7), pp.831-841. ⟨10.1016/j.jval.2019.11.009⟩. ⟨hal-02972372⟩